Last reviewed · How we verify
ABT-143
ABT-143 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.
ABT-143 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | ABT-143 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ABT-143 functions as a bispecific antibody designed to bind and modulate multiple immune pathways simultaneously, thereby overcoming tumor immune evasion. By targeting complementary checkpoint pathways, the drug aims to achieve synergistic T-cell activation and proliferation. This dual-targeting approach is intended to improve anti-tumor immunity compared to single-checkpoint inhibitors.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia (PHASE3)
- Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides (PHASE3)
- Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form. (PHASE1)
- Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium (PHASE1)
- Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium (PHASE1)
- Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg (PHASE1)
- Assessment of the Effect of Food on ABT-143 Bioavailability (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-143 CI brief — competitive landscape report
- ABT-143 updates RSS · CI watch RSS
- AstraZeneca portfolio CI